Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

• Status: Completed
• Trial end date: 2016-01-27
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma S.A.S.
• Treatments: Antifungal Agents; Echinocandins; Micafungin; Miconazole

Criteria

Inclusion Criteria:

• Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.

• Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.

• Patient initiating antifungal prophylaxis with micafungin.

Exclusion Criteria:

• Patient presenting documented fungal infection.

• Patient already included in a biomedical study impacting the care management of invasive fungal infection at the time of inclusion.